Logo image of VCEL

VERICEL CORP (VCEL) Stock Price, Quote, News and Overview

NASDAQ:VCEL - Nasdaq - US92346J1088 - Common Stock - Currency: USD

42.48  +0.99 (+2.39%)

After market: 42.48 0 (0%)

VCEL Quote, Performance and Key Statistics

VERICEL CORP

NASDAQ:VCEL (5/16/2025, 8:00:01 PM)

After market: 42.48 0 (0%)

42.48

+0.99 (+2.39%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High63
52 Week Low37.39
Market Cap2.13B
Shares50.14M
Float49.62M
Yearly DividendN/A
Dividend YieldN/A
PE1416
Fwd PE55.81
Earnings (Next)07-30 2025-07-30/bmo
IPO02-04 1997-02-04


VCEL short term performance overview.The bars show the price performance of VCEL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

VCEL long term performance overview.The bars show the price performance of VCEL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40

The current stock price of VCEL is 42.48 USD. In the past month the price increased by 3.03%. In the past year, price decreased by -12.14%.

VERICEL CORP / VCEL Daily stock chart

VCEL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.92 325.53B
AMGN AMGEN INC 13.12 146.46B
GILD GILEAD SCIENCES INC 13.24 127.61B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.77B
REGN REGENERON PHARMACEUTICALS 13.41 64.17B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.11B
ARGX ARGENX SE - ADR 96.36 34.54B
ONC BEIGENE LTD-ADR 5.68 24.62B
BNTX BIONTECH SE-ADR N/A 22.30B
NTRA NATERA INC N/A 20.74B
BIIB BIOGEN INC 7.94 18.40B
SMMT SUMMIT THERAPEUTICS INC N/A 17.73B

About VCEL

Company Profile

VCEL logo image Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 357 full-time employees. The firm is a provider of advanced therapies for the sports medicine and severe burn care markets. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

Company Info

VERICEL CORP

64 Sidney St

Cambridge MASSACHUSETTS 02139 US

CEO: Dominick C. Colangelo

Employees: 357

VCEL Company Website

VCEL Investor Relations

Phone: 17349305555

VERICEL CORP / VCEL FAQ

What is the stock price of VERICEL CORP today?

The current stock price of VCEL is 42.48 USD. The price increased by 2.39% in the last trading session.


What is the ticker symbol for VERICEL CORP stock?

The exchange symbol of VERICEL CORP is VCEL and it is listed on the Nasdaq exchange.


On which exchange is VCEL stock listed?

VCEL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERICEL CORP stock?

14 analysts have analysed VCEL and the average price target is 64.52 USD. This implies a price increase of 51.87% is expected in the next year compared to the current price of 42.48. Check the VERICEL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERICEL CORP worth?

VERICEL CORP (VCEL) has a market capitalization of 2.13B USD. This makes VCEL a Mid Cap stock.


How many employees does VERICEL CORP have?

VERICEL CORP (VCEL) currently has 357 employees.


What are the support and resistance levels for VERICEL CORP (VCEL) stock?

VERICEL CORP (VCEL) has a support level at 38.94 and a resistance level at 42.49. Check the full technical report for a detailed analysis of VCEL support and resistance levels.


Is VERICEL CORP (VCEL) expected to grow?

The Revenue of VERICEL CORP (VCEL) is expected to grow by 20.06% in the next year. Check the estimates tab for more information on the VCEL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERICEL CORP (VCEL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERICEL CORP (VCEL) stock pay dividends?

VCEL does not pay a dividend.


When does VERICEL CORP (VCEL) report earnings?

VERICEL CORP (VCEL) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of VERICEL CORP (VCEL)?

The PE ratio for VERICEL CORP (VCEL) is 1416. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 42.48 USD. Check the full fundamental report for a full analysis of the valuation metrics for VCEL.


What is the Short Interest ratio of VERICEL CORP (VCEL) stock?

The outstanding short interest for VERICEL CORP (VCEL) is 9.32% of its float. Check the ownership tab for more information on the VCEL short interest.


VCEL Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to VCEL. When comparing the yearly performance of all stocks, VCEL is a bad performer in the overall market: 79.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VCEL Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to VCEL. VCEL scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VCEL Financial Highlights

Over the last trailing twelve months VCEL reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS increased by 400% compared to the year before.


Industry RankSector Rank
PM (TTM) 4.37%
ROA 2.39%
ROE 3.55%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-187.5%
Sales Q2Q%2.57%
EPS 1Y (TTM)400%
Revenue 1Y (TTM)20.1%

VCEL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to VCEL. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 87% and a revenue growth 20.06% for VCEL


Ownership
Inst Owners107.75%
Ins Owners0.97%
Short Float %9.32%
Short Ratio8.77
Analysts
Analysts87.14
Price Target64.52 (51.88%)
EPS Next Y87%
Revenue Next Year20.06%